#	Pagina
attuale pagina	/open-h2020/projects/212213/index.html

Opendata, web and dolomites

HypoRuLight

Hypoxic Tumour Models for Photoactivatable Ruthenium-based Chemotherapy

Total Cost €

EC-Contrib. €

Partnership

Views

HypoRuLight project word cloud

Explore the words cloud of the HypoRuLight project. It provides you a very rough idea of what is the project "HypoRuLight" about.

agents prodrug therapy ruthenium whereas compounds tumour concentrations treatment class diseased hypoxic looks starting patent absorbing network demonstrating vivo erc resistance molecular business leads activation ru tumours patient efficacy chemotherapy plan commercial tested proof treat therapies clinics light thereby local irradiation normoxic oxygen grant cells parallel photoactivated phototherapy collaborators pdt consequence toxicity cancer tissue mechanisms photodynamic limiting attorney lowering anticancer kill clinical pact models

Project "HypoRuLight" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT LEIDEN Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2311 EZ website: www.universiteitleiden.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2017-PoC
Funding Scheme	ERC-POC
Starting year	2017
Duration (year-month-day)	from 2017-10-01 to 2019-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT LEIDEN UNIVERSITEIT LEIDEN Organization address address: RAPENBURG 70 city: LEIDEN postcode: 2311 EZ website: www.universiteitleiden.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	coordinator	150˙000.00

Map

Project objective

In this Proof-of-Concept project I will show the commercial potential of ruthenium-based photoactivated chemotherapy (PACT) compounds developed in my ERC Starting Grant by demonstrating their efficacy on hypoxic cancer models. Photoactivated chemotherapy is a new class of phototherapy to treat cancer. In principle, PACT looks similar to photodynamic therapy (PDT): light irradiation of the tumour in vivo leads to local activation of the anticancer prodrug, thereby limiting the toxicity of the treatment to the diseased tissue, and thus lowering side effects for the patient. However, the mechanisms of PACT and PDT are very different: in PDT the light-absorbing prodrug requires molecular oxygen to kill the cancer cells, whereas in PACT oxygen is not involved in prodrug activation. As a consequence, PACT agents should be able to treat hypoxic tumours, which are characterized by low oxygen concentrations and high resistance to PDT and other existing therapies. In this project the efficacy of a selection of Ru-based PACT compounds will be tested in hypoxic cancer models and compared to their efficacy in normoxic conditions. In parallel I will develop, in collaboration with my network of collaborators from the clinics, business analysts, and patent attorney, a plan for (pre) clinical development of PACT compounds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPORULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPORULIGHT" are provided by the European Opendata Portal: CORDIS opendata.